Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.

Kang CC, Ward TM, Bockhorn J, Schiffman C, Huang H, Pegram MD, Herr AE.

NPJ Precis Oncol. 2018 Mar 22;2:10. doi: 10.1038/s41698-018-0052-3. eCollection 2018.

2.

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.

Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC.

Mol Cancer Ther. 2018 May;17(5):1133-1142. doi: 10.1158/1535-7163.MCT-17-0827. Epub 2018 Feb 26.

PMID:
29483213
3.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.

Oncotarget. 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727.

4.

Neratinib in ERBB2-Positive Brain Metastases.

Pegram MD.

JAMA Oncol. 2016 Dec 1;2(12):1541-1543. doi: 10.1001/jamaoncol.2016.0238. No abstract available.

PMID:
27077740
5.

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD.

Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26.

6.

Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology.

Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D.

Oncotarget. 2016 Mar 15;7(11):12748-60. doi: 10.18632/oncotarget.7220.

7.

COUNTERPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.

Pegram MD.

Oncology (Williston Park). 2015 Nov;29(11):797, 801-2. No abstract available.

8.

Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.

Duncombe TA, Kang CC, Maity S, Ward TM, Pegram MD, Murthy N, Herr AE.

Adv Mater. 2016 Jan 13;28(2):327-334. doi: 10.1002/adma.201503939. Epub 2015 Nov 16.

9.

"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.

Sledge GW, Pegram MD.

Clin Cancer Res. 2015 Jun 15;21(12):2663-5. doi: 10.1158/1078-0432.CCR-14-3183. Erratum in: Clin Cancer Res. 2015 Sep 1;21(17):4024.

10.

Everything old is neu again: cellular senescence in HER2-positive breast cancer.

Sledge GW, Pegram MD.

J Natl Cancer Inst. 2015 May 13;107(5). pii: djv091. doi: 10.1093/jnci/djv091. Print 2015 May. No abstract available.

PMID:
25972602
11.

Personalization of loco-regional care for primary breast cancer patients (part 2).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1301-5. doi: 10.2217/fon.15.66.

12.

Personalization of loco-regional care for primary breast cancer patients (part 1).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1297-300. doi: 10.2217/fon.15.65.

13.

Rapid reduction in breast cancer mortality with inorganic arsenic in drinking water.

Smith AH, Marshall G, Yuan Y, Steinmaus C, Liaw J, Smith MT, Wood L, Heirich M, Fritzemeier RM, Pegram MD, Ferreccio C.

EBioMedicine. 2014 Nov 1;1(1):58-63.

14.

Treating the HER2 pathway in early and advanced breast cancer.

Pegram MD.

Hematol Oncol Clin North Am. 2013 Aug;27(4):751-65, viii. doi: 10.1016/j.hoc.2013.05.007. Review.

PMID:
23915743
15.

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD.

Breast Cancer Res Treat. 2013 Apr;138(3):783-94. doi: 10.1007/s10549-013-2497-y. Epub 2013 Mar 31.

PMID:
23542956
16.

Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.

Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T.

Breast Cancer Res Treat. 2012 Dec;136(3):919-26. doi: 10.1007/s10549-012-2333-9. Epub 2012 Nov 11.

PMID:
23143284
17.

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.

Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD.

Breast Cancer Res Treat. 2012 Dec;136(3):683-92. doi: 10.1007/s10549-012-2252-9. Epub 2012 Oct 23.

PMID:
23089982
18.

Tumor biology trumps anatomy in breast cancer brain metastases.

Pegram MD.

Oncology (Williston Park). 2012 Jul;26(7):666, 668, 670. No abstract available.

19.

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.

Ward TM, Iorns E, Liu X, Hoe N, Kim P, Singh S, Dean S, Jegg AM, Gallas M, Rodriguez C, Lippman M, Landgraf R, Pegram MD.

Oncogene. 2013 May 9;32(19):2463-74. doi: 10.1038/onc.2012.256. Epub 2012 Jul 2.

20.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S.

Breast Cancer Res Treat. 2012 Feb;132(1):215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec 3.

21.

Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Smith TR, Liu-Mares W, Van Emburgh BO, Levine EA, Allen GO, Hill JW, Reis IM, Kresty LA, Pegram MD, Miller MS, Hu JJ.

Carcinogenesis. 2011 Sep;32(9):1354-60. doi: 10.1093/carcin/bgr117. Epub 2011 Jun 23.

22.

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD.

Breast Cancer Res Treat. 2011 Oct;129(3):659-74. doi: 10.1007/s10549-011-1632-x. Epub 2011 Jun 23.

PMID:
21698410
23.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ.

J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29.

PMID:
21115860
24.

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.

Harbeck N, Pegram MD, Rüschoff J, Möbus V.

Breast Care (Basel). 2010;5(s1):3-7. Epub 2010 Apr 26.

25.

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N.

Breast Cancer Res. 2009;11(5):R73. doi: 10.1186/bcr2409.

26.

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ.

Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29.

PMID:
19179558
27.

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd.

J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19.

PMID:
18490651
28.

Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts.

Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DH.

J Nucl Med. 2007 Dec;48(12):2021-7. Epub 2007 Nov 15.

29.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology/College of American Pathologists.

Arch Pathol Lab Med. 2007;131(1):18-43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2.

PMID:
19548375
30.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189
31.

Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.

Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2006 Dec;47(12):1995-9.

32.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.

J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
16896006
33.

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ.

J Clin Oncol. 2006 Apr 20;24(12):1831-8. Epub 2006 Mar 20. Erratum in: J Clin Oncol. 2006 Jul 20;24(21):3515. Powell, Jodeen E [added].

PMID:
16549824
34.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.

35.

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.

Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ.

Ann Oncol. 2006 Apr;17(4):597-604. Epub 2006 Jan 10.

PMID:
16403812
36.

Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.

Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH.

Mol Imaging Biol. 2006 Jan-Feb;8(1):36-42.

PMID:
16362149
37.

Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.

Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DH.

J Nucl Med. 2005 Nov;46(11):1866-71.

38.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Yeon CH, Pegram MD.

Invest New Drugs. 2005 Oct;23(5):391-409. Review.

PMID:
16133791
39.

Targeted therapy: wave of the future.

Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G.

J Clin Oncol. 2005 Mar 10;23(8):1776-81. Review. No abstract available.

PMID:
15755985
40.

Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.

Konecny GE, Pegram MD.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):32-6. Review.

41.

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.

Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ.

J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51.

PMID:
15292386
42.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ.

J Natl Cancer Inst. 2004 May 19;96(10):759-69.

PMID:
15150304
43.

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ.

J Natl Cancer Inst. 2004 May 19;96(10):739-49.

PMID:
15150302
44.

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.

Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD.

Clin Cancer Res. 2004 Mar 1;10(5):1706-16.

45.

Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.

Gilbert CW, McGowan EB, Seery GB, Black KS, Pegram MD.

J Exp Ther Oncol. 2003 Jan-Feb;3(1):27-35.

PMID:
12724856
46.
47.

Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

Pegram MD, O'Callaghan C.

Clin Breast Cancer. 2001 Oct;2 Suppl 1:S15-9. Review.

PMID:
11970740
48.

Docetaxel and herceptin: foundation for future strategies.

Pegram MD.

Oncologist. 2001;6 Suppl 3:22-5. Review.

49.

Trastuzumab and chemotherapeutics: drug interactions and synergies.

Pegram MD, Lopez A, Konecny G, Slamon DJ.

Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100.

PMID:
11236023
50.

Supplemental Content

Loading ...
Support Center